Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's top brokers have been busy adjusting their financial models again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why they are feeling bullish on them right now:

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate

Image source: Getty Images

Hub24 Ltd (ASX: HUB)

According to a note out of Morgan Stanley, its analysts have retained their overweight rating and $44.00 price target on this investment platform provider's shares. This follows the release of the company's third-quarter update this week. Morgan Stanley highlights that the company's platform funds under administration (FUA) of $79.7 billion came in ahead of its estimates. In light of this and higher seasonal flows, the broker sees scope for the company to outperform in the fourth quarter. The broker was also pleased to see management reaffirm its guidance for platform FUA to reach $92 billion to 100 billion in FY 2025. The HUB24 share price is trading at $39.62 this afternoon.

Pro Medicus Limited (ASX: PME)

A note out of Goldman Sachs reveals that its analysts have initiated coverage on this health imaging company's shares with a buy rating and $134.00 price target. The broker sees Pro Medicus as the clear incumbent technology leader in a growing market with a strong financial profile and significant artificial intelligence upside. Goldman believes that the company's Visage 7 platform is core to many healthcare institutions, providing efficiency gains in a market where demand for imaging continues to grow and radiologist shortages persist. It thinks it can increase its US market share to 13% in FY 2030 from ~7% today. The Pro Medicus share price is fetching $101.94 on Wednesday.

Zip Co Ltd (ASX: ZIP)

Analysts at UBS have retained their buy rating on this buy now pay later provider's shares with an improved price target of $1.55. This follows the release of the company's third-quarter update this week which revealed a 14.6% increase in total transaction volume and a 26.6% jump in revenue. UBS was pleased with the stronger-than-expected update. It notes that it was driven by a particularly strong performance from its Zip Americas business. And while it was slightly disappointed with the performance of the Zip AU business, it believes this will stabilise in FY 2025 and then return to growth. Overall, the broker was impressed and its earnings estimates have been revised higher. The Zip share price is trading at $1.14 on Wednesday afternoon.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Hub24, Pro Medicus, and Zip Co. The Motley Fool Australia has recommended Hub24 and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »

Wlorker on a laptop on top of solar panels.
Broker Notes

Up 8%, should I buy the rebound in Origin Energy shares today?

A leading analyst provides his forecast for Origin Energy’s rebounding shares.

Read more »

A woman stands in a field and raises her arms to welcome a golden sunset.
Gold

4 ASX 200 gold shares to buy: Experts

Experts explain their buy ratings following these miners' June quarter reports.

Read more »

Three balls at various places on a cycle.
Broker Notes

6 ASX uranium shares to buy ahead of yellow cake rising to US$200 per pound: experts

This broker tips 83% to 295% upside over 12 months for its 6 top ASX uranium share picks.

Read more »

A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.
Broker Notes

Buy, hold, sell: Capstone Copper, Lindsay Australia, Woodside shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 23% and 58%, should I buy TechnologyOne and Xero shares now?

A leading expert provides his forecasts for TechnologyOne and Xero shares.

Read more »